TY  - JOUR

T1  - Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets)

JO  - Annals of Oncology

PY  - 2014/09/01

AU  - Logue J

AU  - Wedel S

AU  - Chodacki A

AU  - Sartor O

AU  - Nilsson S

AU  - Coleman RE

AU  - James N

AU  - Aksnes A

AU  - Wahba M

AU  - Parker C

ED  - 

DO  - DOI: 10.1093/annonc/mdu336.18

PB  - Elsevier BV

VL  - 25

SP  - iv264

EP  - iv264

Y2  - 2025/10/10

ER  -